SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients

Metformin remains the first pharmacological choice for treating hyperglycemia in type 2 diabetes (T2DM) in most international guidelines. Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are increasingly used as add-on therapy. T2DM pathophysiology is different in Asian and non-Asian (mainly...

Descripción completa

Detalles Bibliográficos
Autor principal: Scheen, André J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417649/
https://www.ncbi.nlm.nih.gov/pubmed/32821142
http://dx.doi.org/10.2147/DMSO.S193528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417649/
https://www.ncbi.nlm.nih.gov/pubmed/32821142
http://dx.doi.org/10.2147/DMSO.S193528

Ejemplares similares